BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 16828529)

  • 41. Head-to-head comparison of four nonadjuvanted inactivated cell culture-derived influenza vaccines: effect of composition, spatial organization and immunization route on the immunogenicity in a murine challenge model.
    Hagenaars N; Mastrobattista E; Glansbeek H; Heldens J; van den Bosch H; Schijns V; Betbeder D; Vromans H; Jiskoot W
    Vaccine; 2008 Dec; 26(51):6555-63. PubMed ID: 18848856
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity.
    Huleatt JW; Jacobs AR; Tang J; Desai P; Kopp EB; Huang Y; Song L; Nakaar V; Powell TJ
    Vaccine; 2007 Jan; 25(4):763-75. PubMed ID: 16968658
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Vaccination with streptococcal extracellular cysteine protease (interleukin-1 beta convertase) protects mice against challenge with heterologous group A streptococci.
    Kapur V; Maffei JT; Greer RS; Li LL; Adams GJ; Musser JM
    Microb Pathog; 1994 Jun; 16(6):443-50. PubMed ID: 7830531
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Modular virus-like particles for sublingual vaccination against group A streptococcus.
    Seth A; Kong IG; Lee SH; Yang JY; Lee YS; Kim Y; Wibowo N; Middelberg AP; Lua LH; Kweon MN
    Vaccine; 2016 Dec; 34(51):6472-6480. PubMed ID: 27866769
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mucosal immunization with polyamine transport protein D (PotD) protects mice against nasopharyngeal colonization with Streptococcus pneumoniae.
    Shah P; Briles DE; King J; Hale Y; Swiatlo E
    Exp Biol Med (Maywood); 2009 Apr; 234(4):403-9. PubMed ID: 19176871
    [TBL] [Abstract][Full Text] [Related]  

  • 46. M protein conserved region antibodies opsonise multiple strains of Streptococcus pyogenes with sequence variations in C-repeats.
    Vohra H; Dey N; Gupta S; Sharma AK; Kumar R; McMillan D; Good MF
    Res Microbiol; 2005 May; 156(4):575-82. PubMed ID: 15862457
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cross-protection between group A and group B streptococci due to cross-reacting surface proteins.
    Stâlhammar-Carlemalm M; Areschoug T; Larsson C; Lindahl G
    J Infect Dis; 2000 Jul; 182(1):142-9. PubMed ID: 10882591
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Identification of the domains of the fibronectin-binding protein I of Streptococcus pyogenes responsible for adjuvanticity.
    Schulze K; Guzmán CA
    FEMS Immunol Med Microbiol; 2003 Jul; 37(2-3):173-7. PubMed ID: 12832122
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mucosal immunization with recombinant heparin-binding haemagglutinin adhesin suppresses extrapulmonary dissemination of Mycobacterium bovis bacillus Calmette-Guérin (BCG) in infected mice.
    Kohama H; Umemura M; Okamoto Y; Yahagi A; Goga H; Harakuni T; Matsuzaki G; Arakawa T
    Vaccine; 2008 Feb; 26(7):924-32. PubMed ID: 18192091
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antibody response in mice immunized by mucosal routes with formalin-inactivated enteropathogenic Escherichia coli (EPEC) strains.
    Drago-Serrano ME; Manjarréz Hernandez HA; Gavilanes Parra S; Sainz Espuñes Tdel R
    Rev Latinoam Microbiol; 2004; 46(1-2):17-23. PubMed ID: 17061522
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Protective immunity against Streptococcus pyogenes challenge in mice after immunization with fibronectin-binding protein.
    Terao Y; Okamoto S; Kataoka K; Hamada S; Kawabata S
    J Infect Dis; 2005 Dec; 192(12):2081-91. PubMed ID: 16288371
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Protective immunity against Toxoplasma challenge in mice by coadministration of T. gondii antigens and Eimeria profilin-like protein as an adjuvant.
    Hedhli D; Dimier-Poisson I; Judge JW; Rosenberg B; Mévélec MN
    Vaccine; 2009 Apr; 27(16):2274-81. PubMed ID: 19428842
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Immunization with recombinant Brucella species outer membrane protein Omp16 or Omp19 in adjuvant induces specific CD4+ and CD8+ T cells as well as systemic and oral protection against Brucella abortus infection.
    Pasquevich KA; Estein SM; García Samartino C; Zwerdling A; Coria LM; Barrionuevo P; Fossati CA; Giambartolomei GH; Cassataro J
    Infect Immun; 2009 Jan; 77(1):436-45. PubMed ID: 18981242
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mucosal vaccination with a multicomponent adenovirus-vectored vaccine protects against Streptococcus pneumoniae infection in the lung.
    Arévalo MT; Xu Q; Paton JC; Hollingshead SK; Pichichero ME; Briles DE; Girgis N; Zeng M
    FEMS Immunol Med Microbiol; 2009 Apr; 55(3):346-51. PubMed ID: 19291171
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Induction of immune responses and prevention of alveolar bone loss by intranasal administration of mice with Porphyromonas gingivalis fimbriae and recombinant cholera toxin B subunit.
    Takahashi Y; Kumada H; Hamada N; Haishima Y; Ozono S; Isaka M; Yasuda Y; Tochikubo K; Umemoto T
    Oral Microbiol Immunol; 2007 Dec; 22(6):374-80. PubMed ID: 17949339
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immunogenicity in mice and non-human primates of the Group A Streptococcal J8 peptide vaccine candidate conjugated to CRM197.
    Caro-Aguilar I; Ottinger E; Hepler RW; Nahas DD; Wu C; Good MF; Batzloff M; Joyce JG; Heinrichs JH; Skinner JM
    Hum Vaccin Immunother; 2013 Mar; 9(3):488-96. PubMed ID: 23249976
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Protection against tuberculosis induced by oral prime with Mycobacterium bovis BCG and intranasal subunit boost based on the vaccine candidate Ag85B-ESAT-6 does not correlate with circulating IFN-gamma producing T-cells.
    Badell E; Nicolle F; Clark S; Majlessi L; Boudou F; Martino A; Castello-Branco L; Leclerc C; Lewis DJ; Marsh PD; Gicquel B; Winter N
    Vaccine; 2009 Jan; 27(1):28-37. PubMed ID: 18977269
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Intranasal immunization with the cholera toxin B subunit-pneumococcal surface antigen A fusion protein induces protection against colonization with Streptococcus pneumoniae and has negligible impact on the nasopharyngeal and oral microbiota of mice.
    Pimenta FC; Miyaji EN; Arêas AP; Oliveira ML; de Andrade AL; Ho PL; Hollingshead SK; Leite LC
    Infect Immun; 2006 Aug; 74(8):4939-44. PubMed ID: 16861686
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immunization with C5a peptidase from either group A or B streptococci enhances clearance of group A streptococci from intranasally infected mice.
    Cleary PP; Matsuka YV; Huynh T; Lam H; Olmsted SB
    Vaccine; 2004 Oct; 22(31-32):4332-41. PubMed ID: 15474726
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Multi-epitope DNA vaccine linked to the A2/B subunit of cholera toxin protect mice against Toxoplasma gondii.
    Cong H; Gu QM; Yin HE; Wang JW; Zhao QL; Zhou HY; Li Y; Zhang JQ
    Vaccine; 2008 Jul; 26(31):3913-21. PubMed ID: 18555564
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.